238 related articles for article (PubMed ID: 21218756)
21. The proton pump inhibitor test and the diagnosis of gastroesophageal reflux disease.
Pace F; Pace M
Expert Rev Gastroenterol Hepatol; 2010 Aug; 4(4):423-7. PubMed ID: 20678016
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic work-up of GERD.
Vela MF
Gastrointest Endosc Clin N Am; 2014 Oct; 24(4):655-66. PubMed ID: 25216910
[TBL] [Abstract][Full Text] [Related]
23. Upper GI tract findings in patients with heartburn in whom proton pump inhibitor treatment failed versus those not receiving antireflux treatment.
Poh CH; Gasiorowska A; Navarro-Rodriguez T; Willis MR; Hargadon D; Noelck N; Mohler J; Wendel CS; Fass R
Gastrointest Endosc; 2010 Jan; 71(1):28-34. PubMed ID: 19922918
[TBL] [Abstract][Full Text] [Related]
24. Erosive esophagitis and NERD: Can we really classify patients with heartburn by endoscopic findings?
Chey WD
Clin Gastroenterol Hepatol; 2004 Aug; 2(8):654-5. PubMed ID: 15290656
[No Abstract] [Full Text] [Related]
25. Clinical, but not oesophageal pH-impedance, profiles predict response to proton pump inhibitors in gastro-oesophageal reflux disease.
Zerbib F; Belhocine K; Simon M; Capdepont M; Mion F; Bruley des Varannes S; Galmiche JP
Gut; 2012 Apr; 61(4):501-6. PubMed ID: 21997546
[TBL] [Abstract][Full Text] [Related]
26. Eight weeks of esomeprazole therapy reduces symptom relapse, compared with 4 weeks, in patients with Los Angeles grade A or B erosive esophagitis.
Hsu PI; Lu CL; Wu DC; Kuo CH; Kao SS; Chang CC; Tai WC; Lai KH; Chen WC; Wang HM; Cheng JS; Tsai TJ; Chuah SK
Clin Gastroenterol Hepatol; 2015 May; 13(5):859-66.e1. PubMed ID: 25245625
[TBL] [Abstract][Full Text] [Related]
27. Clinical trial: factors associated with freedom from relapse of heartburn in patients with healed reflux oesophagitis--results from the maintenance phase of the EXPO study.
Labenz J; Armstrong D; Zetterstrand S; Eklund S; Leodolter A
Aliment Pharmacol Ther; 2009 Jun; 29(11):1165-71. PubMed ID: 19298581
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness of proton pump inhibitors in nonerosive reflux disease.
Dean BB; Gano AD; Knight K; Ofman JJ; Fass R
Clin Gastroenterol Hepatol; 2004 Aug; 2(8):656-64. PubMed ID: 15290657
[TBL] [Abstract][Full Text] [Related]
29. Evolving issues in the management of reflux disease?
Yuan Y; Hunt RH
Curr Opin Gastroenterol; 2009 Jul; 25(4):342-51. PubMed ID: 19417644
[TBL] [Abstract][Full Text] [Related]
30. Esomeprazole for the Treatment of Erosive Esophagitis in Children: An International, Multicenter, Randomized, Parallel-Group, Double-Blind (for Dose) Study.
Tolia V; Youssef NN; Gilger MA; Traxler B; Illueca M
J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S24-30. PubMed ID: 26121347
[TBL] [Abstract][Full Text] [Related]
31. Esomeprazole for the Treatment of Erosive Esophagitis in Children: An International, Multicenter, Randomized, Parallel-Group, Double-Blind (for Dose) Study.
Tolia V; Youssef NN; Gilger MA; Traxler B; Illueca M
J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S24-30. PubMed ID: 26422095
[TBL] [Abstract][Full Text] [Related]
32. Impairment of chemical clearance is relevant to the pathogenesis of refractory reflux oesophagitis.
Frazzoni M; Bertani H; Manta R; Mirante VG; Frazzoni L; Conigliaro R; Melotti G
Dig Liver Dis; 2014 Jul; 46(7):596-602. PubMed ID: 24709005
[TBL] [Abstract][Full Text] [Related]
33. Factors associated with complicated erosive esophagitis: A Japanese multicenter, prospective, cross-sectional study.
Sakaguchi M; Manabe N; Ueki N; Miwa J; Inaba T; Yoshida N; Sakurai K; Nakagawa M; Yamada H; Saito M; Nakada K; Iwakiri K; Joh T; Haruma K
World J Gastroenterol; 2017 Jan; 23(2):318-327. PubMed ID: 28127205
[TBL] [Abstract][Full Text] [Related]
34. Antireflux surgery in the proton pump inhibitor era.
Bulsiewicz WJ; Madanick RD
Cleve Clin J Med; 2012 Apr; 79(4):273-81. PubMed ID: 22473727
[TBL] [Abstract][Full Text] [Related]
35. An open non-comparative clinical study for the evaluation of safety and efficacy of esomeprazole in patients of reflux oesophagitis in Indian population.
Dinakaran NH; Rajkumar JS; Potdar NP; Desai A
J Indian Med Assoc; 2002 Oct; 100(10):624-6. PubMed ID: 12452520
[TBL] [Abstract][Full Text] [Related]
36. Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they?
de Bortoli N; Martinucci I; Savarino E; Bellini M; Bredenoord AJ; Franchi R; Bertani L; Furnari M; Savarino V; Blandizzi C; Marchi S
Neurogastroenterol Motil; 2014 Jan; 26(1):28-35. PubMed ID: 23992024
[TBL] [Abstract][Full Text] [Related]
37. How to differentiate non-erosive reflux disease from functional heartburn.
Ke MY
J Dig Dis; 2012 Dec; 13(12):605-8. PubMed ID: 23134478
[TBL] [Abstract][Full Text] [Related]
38. Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: a systematic overview.
Chiba N
Can J Gastroenterol; 1997 Sep; 11 Suppl B():66B-73B. PubMed ID: 9347181
[TBL] [Abstract][Full Text] [Related]
39. Review article: physiologic and clinical effects of proton pump inhibitors on non-acidic and acidic gastro-oesophageal reflux.
Miner PB
Aliment Pharmacol Ther; 2006 Mar; 23 Suppl 1():25-32. PubMed ID: 16483267
[TBL] [Abstract][Full Text] [Related]
40. The long-term follow-up of patients with endoscopically diagnosed reflux oesophagitis with specific emphasis to complaints.
Loffeld SM; Dackus GM; Loffeld RJ
Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1122-6. PubMed ID: 21934510
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
